 |
   
|
  |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
Telaprevir Under Study for HIV/HCV CoinfectionWinter/Spring 2010 The investigational hepatitis C virus (HCV) protease inhibitor telaprevir -- the furthest along of the new directly targeted antiviral agents -- is now being tested in HIV/HCV coinfected individuals. The drug has demonstrated good antiviral activity in combination with pegylated interferon plus ribavirin in clinical trials of people with hepatitis C alone, and developer Vertex Pharmaceuticals plans to request FDA approval in the second half of this year. For further information, see "Open Clinical Trials." Liz Highleyman (liz@black-rose.com) is a freelance medical writer based in San Francisco.  This article was provided by San Francisco AIDS Foundation. It is a part of the publication Bulletin of Experimental Treatments for AIDS. Visit San Francisco AIDS Foundation's Web site to find out more about their activities, publications and services.
Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before adding your comment, please read TheBody.com's Comment Policy.) |
|
Email
Comments
Print-Friendly
Glossary
PDF
The Body: About The Body | Contact The Body | Content Policy | Content Providers | Advertise With Us | Site Map
Remedy Health Media: About Remedy Health Media | Contact Remedy Health Media | Terms of Use | Privacy Policy
The Body is a service of Remedy Health Media, LLC, 500 5th Avenue, 19th Floor, New York, NY 10110. The Body and its logos are trademarks of Remedy Health Media, LLC, and its subsidiaries, which owns the copyright of The Body's homepage, topic pages, page designs and HTML code. General Disclaimer: The Body is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.
